Evidence map›Paper›PMID 35743778›Full record

ArticleJournal of personalized medicine2022

Serological Response and Relationship with Gender-Sensitive Variables among Healthcare Workers after SARS-CoV-2 Vaccination.

Roberto Cangemi, Manuela Di Franco, Antonio Angeloni, Alessandra Zicari, Vincenzo Cardinale, Marcella Visentini, Guido Antonelli, Anna Napoli, Emanuela Anastasi, Giulio Francesco Romiti and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Roberto CangemiDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Roma, Italy.ORCID 0000-0002-4097-2061
Manuela Di FrancoDepartment of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Roma, Italy.
Antonio AngeloniDepartment of Experimental Medicine, Sapienza University of Rome, 00185 Roma, Italy.
Alessandra ZicariDepartment of Experimental Medicine, Sapienza University of Rome, 00185 Roma, Italy.
Vincenzo CardinaleDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00185 Roma, Italy.
Marcella VisentiniDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Roma, Italy.
Guido AntonelliDepartment of Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy.
Anna NapoliDepartment of Molecular Medicine, Sapienza University of Rome, 00185 Roma, Italy.
Emanuela AnastasiDepartment of Experimental Medicine, Sapienza University of Rome, 00185 Roma, Italy.ORCID 0000-0002-5124-3219
Giulio Francesco RomitiDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Roma, Italy.ORCID 0000-0002-3788-8942
Fabrizio d'AlbaGeneral Direction, Umberto I Hospital, 00161 Roma, Italy.
Domenico AlvaroDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Roma, Italy.
Antonella PolimeniDepartment of Oral and Maxillofacial Science, Sapienza University of Rome, 00185 Roma, Italy.ORCID 0000-0002-2679-7607
Stefania BasiliDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Roma, Italy.ORCID 0000-0002-6987-1926
Sapienzavax Collaborators
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccine-induced immunity is a key strategy in the long-term control of the COVID-19 pandemic. The aim of our study was to explore the relationship between mRNA vaccine-induced antibodies and gender-sensitive variables among healthcare workers. Two thousand-sixty-five volunteers who received the BNT162b2 vaccine were enrolled in the study and followed up. Demographic, clinical, and social variables (educational level, marital status, occupation, childcare) were evaluated through a self-administered questionnaire. Anti-Spike (S) IgG were measured at 1 month (T1) and at 5 months (T2) after the second vaccine dose. At T1, median anti-S IgG values were 693 [394−>800] AU/mL (1 AU = 2.6 BAU). Values > 800 AU/mL (2080 BAU/mL) were directly associated with a previous COVID-19 (p < 0.001) infection and inversely with age (p < 0.001), smoking habit (p < 0.001), and autoimmune diseases (p < 0.001). At T2, a significant decreasing in anti-S IgG values was observed (187 [81−262] AU/mL), with a median decrease of 72 [60−82]%. On multivariate data analysis, a reduction of more than 82% was directly associated with male sex (p < 0.021), age (p < 0.001), smoking (p = 0.038), hypertension (p = 0.042), and, inversely, with previous COVID-19 infection (p < 0.001) and being “cohabiting” (p = 0.005). Our findings suggest that demographic, clinical, and social variables play a role in anti-S IgG values decreasing in long-term follow up and should be considered to find personalized vaccine schedules.

Indexed as

antibody responseBNT162b2COVID-19mRNA vaccineSARS-CoV-2

Identifiers

PMID35743778
PMCPMC9225338
OpenAlexW4283119373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.